- Asbestos
- Class Actions
- Commercial Litigation
- Defective Products
- Drug Injury
- Personal Injury
- Securities Fraud
- Toxic Exposure
- Accutane Side Effects
- Darvon and Darvocet
- DePuy Hip Recall
- Fosamax Femur Fractures
- Muscle Injury
- Sleeping Pill Dangers
- SSRI Birth Defects
- Topamax Birth Defects
- Transvaginal Surgical Mesh and Bladder Slings
- Tylenol Liver Damage
- Zocor/Simvastatin
Pending Settlements
Category : Seeger Weiss News
Seeger Weiss Represents Former NFL Players in Concussion Suit
Seeger Weiss LLP is currently representing a group of eleven former professional football players in a lawsuit against the National Football League. The players - Joe Horn, Chris Walsh, Jim Finn, Scott Dragos, Jerome Pathon, Isaiah Kacyvenski, Brad Scioli, Matt Joyce, Sean Ryan, Paul Zukauskas and Sean Berton - allege that the NFL failed to take necessary steps to protect them from long-term brain injuries in the face of overwhelming medical evidence that on-field concussions lead directly to such injuries. The suit also contends that NFL officials – including the League’s own medical committee – repeatedly concealed from players risks associated with concussions and also dangerous side effects of medication administered by NFL personnel.
An important new element to the lawsuit is its focus on a potent anti-inflammatory medication called Toradol. Players allege that they were repeatedly administered the drug, often just prior to games, to reduce on-field pain, a practice that is reportedly still widely condoned by NFL teams today. Medical experts have found that Toradol – manufactured by Roche – can mask symptoms of head injury while inducing greater cerebral bleeding, greatly increasing the risk of long-term brain damage.
“The use of pain reducing, non-steroidal anti-inflammatory drugs such as Toradol in professional sports is a dangerous practice potentiating greater injury and long-term damage to players,” said Christopher Seeger, founding partner of Seeger Weiss LLP. “This is especially relevant in the case of concussions in the NFL due to the extreme high- impact forces incurred, the highly competitive nature of the players, the environment that fosters post-injury play and the importance of the brain to human function.”
In addition to Mr. Seeger, the players are represented by Marc Albert of the Law Offices of Marc S. Albert, as well as James Cecchi of the New Jersey firm of Carella, Byrne, Cecchi, Olstein, Brody & Agnello, P.C.
Click here to read more about this ground-breaking case, or visit Seeger Weiss’ website for more information about this acclaimed national plaintiffs’ firm.
Bloomberg: 10,000 Actos Cancer Claims in U.S.
A major report published by Bloomberg Businessweek today found that Takeda Pharmaceuticals, the manufacturers of the drug Actos, could face as many as 10,000 drug injury lawsuits in the United States. The claimants allege that the diabetes medication caused them to develop bladder cancer. In fact, the number of drug injury suits involving Actos being brought to court has become so massive that a group of judges is being polled to decide whether or not to consolidate the litigation. Learn more about the link between Actos and bladder cancer.
In a legal environment like this one, victims of Actos drug injury need an experienced and dedicated law firm in their corners in order to ensure their claims receive the attention they deserve. If you or someone you know has suffered complications as a result of taking Actos, contact Seeger Weiss LLP today. An attorney with our award-winning drug injury class action practice will assist you in evaluating your claim. Attorney consultations incur no obligation on your part and all initial consultations are free of charge. Seeger Weiss LLP has office locations in New York, New Jersey, Pennsylvania and California.
Fosamax Lawsuits On the Rise, Drug Injury Experts Warn of Fractures
As lawsuits against Fosamax manufacturer, Merck & Co. emerge around the country, drug injury experts are warning patients and doctors about the drug’s harmful side effects. Most notably, the medication, which is indicated to strengthen the bones of those at risk for osteoporosis, has actually been said to make bones weaker, causing an array of unusual problems. Because of such claims, the FDA is expected to publish official warnings about Fosamax later this month. Sheryl Vondracek, an associate professor at the University of Colorado’s Department of Clinical Pharmacy cited in this article, notes that “osteoporosis of the jaw…has been reported with longer term use and atypical fractures, which are fractures of the femur, or thigh bone.”
The experienced drug injury attorneys of Seeger Weiss are actively investigating the claims of those who have been harmed by Fosamax. Click here to visit our Fosamax page.
Drug Injury Claims Cause Actos Sales to Plunge
Reports surfaced early today that profits for Japan-based Takeda Pharmaceutical Co. have substantially declined. One factor that several news sources, including Bloomberg Businessweek, have attributed to the company’s losses is the controversy surrounding its top-selling drug, Actos. Calls for the FDA to release cautionary warnings for the diabetes medication began to emerge after it was linked to an increased risk of bladder cancer. Takeda projects that its net income will plunge by over 30 percent over the course of the next four months.
Seeger Weiss’ highly experienced drug injury practice is closely monitoring reports of bladder cancer associated with Actos. To learn more, visit our Actos investigation page.
Drug Injury Specialists Warn of Actos Side Effects
Following negative media attention and a swarm of recent pharmaceutical drug litigation involving the medication, the European Commission has requested that the European Medicines Agency (EMA) clarify its position on the use of Actos. Both France and Germany prohibited the diabetes drug after reports indicated that it increased patients’ risk of heart attack and bladder cancer. Although the FDA did not officially ban Actos in the U.S., it added warnings to its label. Now, the EMA has asserted that while the drug can be a “valid treatment” for type 2 diabetes, it should only be prescribed when other medications have failed. Furthermore, the agency urges doctors who prescribe Actos to closely monitor their patients. Read the full story.
The experienced pharmaceutical injury attorneys in Seeger Weiss’ drug injury practice are closely following developments about reported Actos side effects. To learn more, visit our Actos Investigation Page.
Merck Faces Another Fosamax Drug Injury Suit
In an Illinois circuit court, two women have filed a drug injury lawsuit against pharmaceutical giant, Merck Sharp & Dohme Corporation. Beth Tobias and Margaret Freiberg both took Fosamax, a drug manufactured by Merck to help prevent fractures in women with osteoporosis. However, both Tobias and Freiberg allege that Fosamax had the opposite effect on them, weakening their bones and actually increasing their risk of bone injury. Read the full story.
Calling on our experience in drug injury cases, including a $4.85 billion dollar settlement in a case involving another Merck drug, Vioxx, Seeger Weiss is currently taking on new Fosamax cases. Visit our Fosamax Investigation Page to learn more.
Former DePuy Spokesperson Joins Class Action Against Company
At the beginning of this month, yet another wrinkle was added to the recent news coverage on DePuy Orthaepedics’ controversial Artificial Surface Replacement (ASR), a hip implant for patients suffering from severe arthritis. In this story, the
United Kingdom Press Association reports that retired gymnast Penny Brown, who appeared in ads for the product after she received a hip replacement herself, is now joining a class action against her former employer. Brown and the 300 other patients involved claim that wore out prematurely leading to further complications or – as in Brown’s case, – the need for additional surgery.
Seeger Weiss is currently investigating claims of patients who were harmed by the hip replacement. For more information, please visit our DePuy Hip Replacement page.
UK Supreme Court Rules that Asbestos Victims be Compensated
Yesterday the UK Supreme Court denied an appeal of a Scottish law, and ruled that victims of asbestos exposure who develop pleural plaques should in fact be allowed to receive compensation for their harm. The insurance companies that brought the appeal argued that since pleural plaques don’t cause any symptoms, they should not have to pay the claims of those who claim to suffer from the condition. However, the Supreme Court sided with Scottish ministers who noted that pleural plaques can lead to more serious diseases like lung cancer, mesothelioma and asbestosis. As a result of the ruling, the insurance companies are likely to have to pay claimants between 7 and 9 million pounds (about 11 to 14 million dollars). One of the victims involved in this case, former shipyard worker John Ferguson said, “I now have pleural plaques and that hangs over my head. I’ve got to get on with my life, but I don’t know how much life I’ve got left in me – I’d like to see people higher up pay for this in some way.”
Both the effects of asbestos exposure and the difficulties of receiving just compensation persist in the United States as well. Click here to learn more about Seeger Weiss’ ongoing asbestos investigation.
Click here to watch the court’s decision and read the full BBC article.
LA Times: FDA Warns Against High Doses of Zocor
In a Los Angeles Times article from the beginning of this summer, writer Chris Woolston reports a recent FDA announcement to include new labels on Zocor that will warn doctors against prescribing his doses of the medication. As Woolston notes, the FDA’s decision came after the drug, which is prescribed for lowering cholestorol, was shown to cause injuries to muscles that can potentially be fatal. Seeger Weiss is currently investigating claims of patients who have been harmed by Zocor.
Learn More about our Zocor Investigation
FDA Panels Recommend Clearer Fosamax Labels
Fosamax, the subject of an ongoing Seeger Weiss investigation, is one of the four brands of bisphosphonates discussed in two advisory panels to the FDA on September 9. Bisphosphonates, drugs prescribed to women at risk of osteoporosis, have in recent years been demonstrated to cause fractures to the femur. Examining the mounting evidence, including the testimony of 18 victims who suffered atypical femoral fractures after taking the medication, the panels voted to recommend more specific instructions for how long Fosamax and other bisphosphonates should be used.
Subscribe to our RSS